These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6846326)

  • 21. Plasma anticoagulant mechanisms of heparin, heparan sulfate, and dermatan sulfate.
    Ofosu FA; Buchanan MR; Anvari N; Smith LM; Blajchman MA
    Ann N Y Acad Sci; 1989; 556():123-31. PubMed ID: 2525356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticoagulant effects of protamine sulfate in a canine model.
    Kresowik TF; Wakefield TW; Fessler RD; Stanley JC
    J Surg Res; 1988 Jul; 45(1):8-14. PubMed ID: 3392995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Placental protein 5 (PP5) inhibits thrombin-induced coagulation of fibrinogen.
    Meisser A; Bischof P; Bohn H
    Arch Gynecol; 1985; 236(4):197-201. PubMed ID: 4026390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of protamine on heparin antithrombin III complexes. In vivo studies.
    Kitani T; Nagarajan SC; Shanberge JN
    Thromb Res; 1980 Feb 1-15; 17(3-4):375-82. PubMed ID: 7368169
    [No Abstract]   [Full Text] [Related]  

  • 25. The effect of human thrombomodulin on the inactivation of thrombin by human antithrombin III.
    Hirahara K; Koyama M; Matsuishi T; Kurata M
    Thromb Res; 1990 Jan; 57(1):117-26. PubMed ID: 2154059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of a synthetic thrombin-inhibitor MD805 on the reaction between thrombin and plasma antithrombin-III.
    Hijikata-Okunomiya A; Okamoto S; Wanaka K
    Thromb Res; 1990 Sep; 59(6):967-77. PubMed ID: 2264021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interrelationship of protamine and platelet factor 4 in the neutralization of heparin.
    Shanberge JN; Quattrociocchi-Longe TM; Martens MH
    Thromb Res; 1987 Apr; 46(1):89-100. PubMed ID: 3590116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitivity of the fibrinogen clotting time: an in vitro test of potential thrombogenicity.
    Feldman PA; McGrath S; Evans H
    Vox Sang; 1994; 66(1):1-7. PubMed ID: 8146976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic effect of antithrombin III, activated protein C and heparin on the inhibition of the tissue thromboplastin-mediated coagulation.
    Hirahara K; Etoh Y; Matsuishi T; Suzuki N; Kurata M
    Chem Pharm Bull (Tokyo); 1989 Mar; 37(3):692-6. PubMed ID: 2752479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of dextran sulphates on thrombin activity.
    Suzuki K; Hashimoto S
    J Clin Pathol; 1979 May; 32(5):439-44. PubMed ID: 469001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heparin binding proteins. Contribution to heparin rebound after cardiopulmonary bypass.
    Teoh KH; Young E; Bradley CA; Hirsh J
    Circulation; 1993 Nov; 88(5 Pt 2):II420-5. PubMed ID: 8222188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo attempt to consume antithrombin III by i.v. injection of a thrombin-heparin mixture.
    Soulier JP; Gozin D; Lerable J
    Thromb Res; 1984 May; 34(3):255-62. PubMed ID: 6729779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anticoagulant properties of extracellular slime substance produced by Staphylococcus epidermidis.
    Bykowska K; Ludwicka A; Wegrzynowicz Z; Lopaciuk S; Kopeć M
    Thromb Haemost; 1985 Dec; 54(4):853-6. PubMed ID: 4089818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The anticoagulant properties of mast cell product, chondroitin sulphate E.
    Scully MF; Ellis V; Seno N; Kakkar VV
    Biochem Biophys Res Commun; 1986 May; 137(1):15-22. PubMed ID: 3087353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antithrombin activity of a fucan sulfate from the brown seaweed Ecklonia kurome.
    Nishino T; Aizu Y; Nagumo T
    Thromb Res; 1991 Jun; 62(6):765-73. PubMed ID: 1926066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anticoagulating activity and lytic action of the heparin-antithrombin III and antithrombin III-heparin-thrombin complexes on non-stabilized fibrin].
    Kudriashov BA; Pastorova VE; Liapina LA
    Biokhimiia; 1981 Nov; 46(11):2024-9. PubMed ID: 7317530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.
    Okwusidi JI; Anvari N; Kulczycky M; Blajchman MA; Buchanan MR; Ofosu FA
    J Lab Clin Med; 1991 May; 117(5):359-64. PubMed ID: 2019790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of heparin activity in plasma by soluble fibrin: evidence for ternary thrombin-fibrin-heparin complex formation.
    Hotchkiss KA; Chesterman CN; Hogg PJ
    Blood; 1994 Jul; 84(2):498-503. PubMed ID: 8025278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of the quantitative action of protamine and heparin on blood coagulation. Significance in clinical and laboratory usage.
    Perkash A
    Am J Clin Pathol; 1980 May; 73(5):676-81. PubMed ID: 7377134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.